Model Number 8637-40 |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Fall (1848); Dizziness (2194); Cognitive Changes (2551); No Code Available (3191)
|
Event Date 06/13/2017 |
Event Type
Injury
|
Manufacturer Narrative
|
If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
Information was received from a healthcare provider (hcp) via a clinical study regarding a patient receiving hydromorphone at an unknown concentration and dose via an implantable infusion pump.It was reported the patient reported dizziness and lightheadedness on (b)(6).The intrathecal rate was decreased in an effort to alleviate the symptoms.The patient was instructed to sit for 15-20 minutes following activating the personal therapy manager (ptm) to help prevent the dizziness and lightheadedness following ptm activations.The clinical diagnosis was intrathecal medication side effects.The outcome was ongoing.The etiology of the event was noted as related to the device or therapy and related to the drug hydromorphone with the drug action that caused the event being therapy initiation.Additional information received from a healthcare provider (hcp) via a clinical study indicated the outcome of the event resolved without sequelae on (b)(6).Interventions included the pump was reprogrammed on (b)(6).On (b)(6), the patient reported hallucinations and episodes of falling.On (b)(6) the patient reported dry mouth following personal therapy manager (ptm) activations.The intrathecal rate was decreased on (b)(6).The correct serial number was provided.Indication for use was spinal pain.No further complications were reported/anticipated.
|
|
Manufacturer Narrative
|
If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
Additional information received from a healthcare provider via a clinical study reported the patient was receiving hydromorphone (0.5 mg/ml at 0.49981 mg/day) and bupivacaine (7.1 mg/ml at 7.0872 mg/day) via an implantable pump.
|
|
Manufacturer Narrative
|
If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
Additional information received from healthcare provider (hcp) via clinical study indicated the cause of the hallucinations, light headedness, dizziness, dry mouth, and episodes of falling was due to therapy initiation.It was noted that the symptoms resolved with reprogramming.The patient's weight was not measured.No further complications were reported/anticipated.
|
|
Search Alerts/Recalls
|